Shots:

• Molecular Templates (MTEM) to receive $38M up front including an equity investment- up to $522M as development- regulatory- commercial milestones- option payment for two targets and royalties on sales of products
• MTEM will conduct research activities to discover a new conditioning regimen utilizing its engineered toxin body (ETB) platform for up to two targets selected by Vertex including CTX001. Additionally- Vertex will get an option to select a second target and to license selected molecules with an exclusive right to develop selected molecules for any indication
• CTX001 is an ex vivo CRISPR/Cas9 gene editing therapy- currently being evaluated in two ongoing P-I/II studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease- where a hematopoietic stem cell transplant is required as part of treatment with CTX001

Click here to­ read full press release/ article 

 Ref: Vertex | Image: Vertex